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Abstract  
Introduction: We investigated factors affecting Virological failure (VF) on first line Antiretroviral Therapy (ART) and evaluated a pragmatic 
approach to switching to second line ART. Methods: Between 2004 and 2011, we assessed adults taking ART. After 6 months or more on ART, 
participants with VL >1000 copies/ml or two successive VL > 400 copies/ml (Conventional VF) received intensified adherence counselling and 
continued on first-line ART for 6 more months, after which participants who still had VL > 1000 copies/ml (Pragmatic VF) were switched to second 
line ART. VF rates were calculated and predictors of failure were found by fitting logistic regression and Cox proportional hazards models. 
Results: The 316 participants accrued 1036 person years at risk (pyar), 84 (26.6%) had conventional VF (rate 8.6 per 100 pyar) of whom 28 
(33.3%) had pragmatic VF (rate 2.7 per 100 pyar). Independent predictors of conventional VF were; alcohol consumption, (adjusted Hazard Ratio; 
aHR = 1.71, 95% CI 1.05-2.79, P = 0.03) and ART adherence: per 10% decrease in proportion of adherent visits, (aHR = 1.83, 95% CI 1.50-2.23; 
P < 0.001). Using reference age group < 30 years, among conventional failures, the adjusted odds ratio (aOR) of pragmatic failure for age group 
30-39 years were 0.12, 95% CI 0.03-0.57, P = 0.02 and for age group > 40 years were 0.14, 95%CI 0.03-0.71, P = 0.02. Alcohol consumers had 
a threefold odds of pragmatic failure than non-alcohol consumers (aOR = 3.14, 95%CI 0.95-10.34, P = 0.06). Conclusion: A pragmatic VF 
approach is essential to guide switching to second line ART. Patient tailored ART adherence counselling among young patients and alcohol users is 
recommended. 
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Introduction 
 
Antiretroviral therapy (ART) has changed the natural history of HIV 
infection [1]. By the end of 2015 about 36.7 million individuals were 
living with HIV globally and 25.8 million of these were living in sub-
Saharan Africa (SSA) [2, 3]. By June 2016, ART coverage had 
increased to 46% globally and 54% in SSA [2]. Uganda's HIV 
prevalence by 2014 was estimated at 7.4% and out of the 
estimated 1.5 million people living with HIV-AIDS (PLWHA)by the 
end of 2014, 0.75 million people were on ART and about 10% of 
these had HIV viral load of above 1000 copies/ml [4]. ART initiation 
reduces HIV replication in peripheral blood [5-8] suppresses plasma 
HIV viral loads (VL) to unquantifiable levels within 4-6 months 
[9, 10], reduces morbidity and mortality, with resultant 
improvement in survival [1, 5]. If adequate viral suppression is not 
achieved, therapy is considered to be failing and may require 
switching to a second line ART regimen [11, 12] which may be both 
expensive and toxic. Like other African countries, Uganda is rolling 
out HIV viral load testing which is expected to increase detection of 
individuals with virological failure who may need second line ART 
regimen [13]. HIV RNA virological monitoring is the gold standard 
for measuring ART progress [14-20]. Although HIV viral suppression 
requires good ART adherence in excess of 95% [21], suboptimal 
viral suppression due to poor adherence has undermined HIV care 
in SSA since introduction of free ART programmes in 2004-2005. 
Many other factors are independently associated with failure to 
achieve optimal HIV viral suppression [19]. Knowledge of such 
predictors will enable clinicians forecast ART outcomes and design 
interventions to prevent virological failure and meet the UNAIDS 90-
90-90 treatment targets. Diagnosis of virological failure based on a 
single plasma VL measurement of > 1000 copies/ml or two 
successive VL measurements above 400 copies/ml, at any time after 
6 months on ART, (conventional VF), has led to unnecessary 
switching from first to second line ART regimen which is costly and 
almost currently the last available treatment option in most SSA 
countries [22]. If patients with detectable VL after 6 months on ART 
receive further intensified ART adherence counselling and continue 
on first-line ART for another 6 months, only those whose VL remains 
>1000 copies/ml (true or pragmatic virological failure) are then 
switched to second-line ART. Until HIV drug resistance testing is 
widely available in public HIV care settings, identifying patients with 
true or pragmatic virological failure provides a more reliable criterion 
for switching patients failing on first line ART to second line ART. 
Studies in developed countries have evaluated switch strategies as a 
basis of enhancing cost savings in an era of global economic 
recession [23]. In this study, we assessed factors affecting 
virological failure using both the conventional and pragmatic 
definitions and justified the use of pragmatically defined virological 
failure while switching patients to second line ART. The study 
findings add to the body of knowledge on ART switching practices in 
resource limited settings and enhances prediction of virological 
failure risk so as to improve ART treatment outcomes. 
  
  
Methods 
 
Study design and setting: The study was based in an open 
prospective HIV Rural Clinical Cohort (RCC) in southwest Uganda. 
The RCC was established in 1990 to study the natural history of 
HIV-1 disease progression and started providing ART and 
cotrimoxazole prophylaxis to eligible participants in 2004 according 
to the existing National Guidelines [24, 25]. First line ART consisted 
of Zidovudine, Lamivudine and either Nevirapine or Efavirenz. Until 
March 2008, patients who were found to be anaemic before or after 
initiation on Zidovudine were switched to Stavudine. In Uganda, 
Stavudine was thereafter gradually replaced by Tenofovir due to its 
toxicity. Second line ART was a combination of Tenofovir, 
Emtricitabine (or Lamivudine from July 2010) and ritonavir boosted 
Lopinavir. At the monthly ART refills, an adherence nurse assessed 
and documented ART and cotrimoxazole prophylaxis self-reported 
adherence and did a pill count. Every quarter, study clinicians 
conducted routine questionnaire interviews, collected medical and 
sexual behaviour history data, and did clinical examination and 
laboratory investigations. Free treatment was provided according to 
the National treatment guidelines [26]. From 2004 to 2011, PLWHA 
individuals aged 13 years and above who initiated and had been on 
ART for 6 months or more with at least 2 plasma viral load 
measurements including one at baseline were included in this 
analysis. 
  
Laboratory methods: CD4 cell counts were measured at ART 
initiation and quarterly using the FACS Count machine (Becton 
Dickinson, San Jose, California, USA). Viral loads were measured at 
ART initiation and 6 monthly, between January 2004 and September 
2007 we used the VERSANT RNA 3.0 (Bayer, Bayer Healthcare, NY, 
USA) assay (lower detection limit of 50 copies per ml), while from 
October 2007 to December 2010 the Amplicor MONITOR 1.5 
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(Roche, Roche molecular systems, NJ, USA) assay was used (lower 
detection limit of 400 copies per ml). 
  
Data management and statistical analysis 
  
Software and participant follow up: Data was managed using 
an Ms Access database and was analysed in Stata version 13.0. 
Participants' characteristics at ART initiation between January 2004 
and March 2011 were summarised by cross tabulation. The study 
had outcomes based on 2 virological failure definitions (conventional 
and pragmatic) at different time points. A participant's follow-up 
started at ART initiation and ended at the earliest time of diagnosis 
of virological failure, death, loss to follow up, or date last seen 
(whichever was first). Loss to follow up was defined as being late 
for 3 months or more after the next scheduled quarterly visit and 
still known to be alive. Participants were censored at the end of the 
study. 
  
Ethics and consent: this study was approved by the Science and 
Ethics Committee of the Uganda Virus Research Institute and the 
Uganda National Council for Science and Technology. Participants 
gave signed or thumb-printed written informed consent to 
participate in the study and confidentiality procedures were adhered 
to throughout the study 
  
Outcome: The main outcome was virological failure. Conventional 
virological failure was defined as a single VL of > 1000 copies/ml or 
two successive VL > 400 copies/ml taken 6 months apart from a 
participant on ART for 6 months or more. Participants with 
conventional virological failure received intensified adherence 
counselling and continued on first line ART for 6 more months after 
which those with persistent VL > 1000 copies/ml were regarded to 
be true or Pragmatic failures and all were switched to second line 
ART regimen. 
  
Exposures: The main exposure was ART adherence which was 
measured monthly at each ART refill visit using both self-report and 
pill count. Participants reported the number of days they missed 
taking their doses over the previous four days and since the last 
ART refill visit. Adherence was categorised as: good (> 95%) if no 
doses were skipped over the last 4 days or since the last refill visit 
and poor (<95%) if any doses were missed over the same period. 
ART adherence data for each participant over the entire follow up 
period or up to the visit of virological failure was collapsed to create 
an overall adherence summary measure. The proportion of visits 
with good adherence was presented for each participant as 
categorical for crude analysis. In addition, the continuous variable 
(proportion of visits with good adherence) was rescaled so that 1 
unit represented a 10% decrease in the proportion of visits with 
good adherence (e.g. from 100% to 90%) and this was used in the 
regression model. Secondary exposures included characteristics 
measured at ART initiation including gender, age, marital status, 
number of partners, occupation, alcohol consumption, CD4 counts, 
HIV viral loads, weight and body mass index (BMI). 
  
Conceptual framework: Our analysis was based on a conceptual 
framework which assumed; ART adherence was independently 
associated with virological failure. Other confounders included; 
socio-demographic (age, gender, marital status, occupation and 
level of education) behavioural (alcohol consumption and number of 
sexual partners) and biological (body mass index, baseline CD4 
counts and baseline VL) risk factors. The association with ART 
adherence was considered distal for apriori confounders age and 
gender and proximal for alcohol consumption. Biological factors 
such as, high baseline VL was associated with low baseline CD4 
counts, poor health, low BMI and poor ART adherence. We also 
assumed that, a high baseline VL provides a potential for ART drug 
resistance mutations which may lead to virological failure [27] 
(Figure 1). 
  
Virological failure rates by categories of explanatory 
variables: Conventional and pragmatic virological failure rates were 
calculated and tabulated for categories of explanatory variables 
using standard survival analysis methods. Kaplan-Meier methods 
were used to estimate time to conventional and pragmatic 
virological failure. The crude hazard ratios and 95% confidence 
intervals (CI) were obtained using Cox regression analysis. The P-
values for the hazard ratios were calculated from the likelihood ratio 
test (LRT). 
  
The effect of adherence on virological failure: Cox regression 
models were used to estimate adjusted hazard ratios (aHR) and 
95% CIs for the effect of adherence on conventional and pragmatic 
virological failure separately. To adjust for confounding, a 
multivariable model was built basing on the conceptual framework. 
A model was fit with the main exposure of interest, adherence, and 
apriori confounders (gender, age and alcohol consumption) and the 
hazard ratio for the exposure of interest was noted. Apriori 
confounders were selected basing on existing literature on their 
potential to affect adherence. Other potential confounders were 
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added one at a time and the effect on the hazard ratio of the main 
exposure was noted. Potential confounding was considered if a 
variable changed the hazard ratio by 10% or more. Collinearity was 
considered if a confounder changed the log10 standard error of the 
main exposure of interest. 
  
Independent predictors of conventional virological failure: A 
model to determine the independent predictors of conventional 
virological failure was based on a conceptual framework. Age, 
alcohol consumption and gender were left in the model as apriori 
confounders and other potential predictors were added one by one 
starting with those considered proximal (Biological) and ending with 
those considered distal in the conceptual framework. Factors were 
only left in the model if the P-value from the LRT was < 0.10. 
Independent predictors of conventional virological failure were 
analysed separately and statistical significance was assessed using 
LRT. 
  
Factors associated with pragmatic failure among the 
conventional failures: The proportion of conventional failures 
that were also pragmatic failures for each level of the explanatory 
variables was calculated separately and logistic regression models 
were fitted to determine factors associated with being a pragmatic 
failure among the conventional failures. The odds ratios and 95% CI 
were estimated and statistical significance was assessed using LRT. 
  
  
Results 
 
Participant's characteristics at ART initiation: A total of 316 
participants were initiated on first line ART from January 2004 to 
December 2011, 63.6% were females, 67.4% had no or incomplete 
primary education, 60.8% were farmers and 29.4% consumed 
alcohol. The median age at ART initiation was 36.5 years with 
62.0% aged below 40 years, range 15 to 75 years. Participants 
initiated ART at a median CD4 count of 156 cells/µl (IQR 73-200) 
and a median VL of 81,758 copies/ml (IQR 26,721-193,184). The 
mean BMI at ART initiation was 20.1kg/m2 (Table 1). We censored 
22 (6%) individuals who initiated ART, 12 (4.1%) died before a 
diagnosis of virological failure (4 males and 8 females) while 10 
(3.2%) were lost to follow up (4 males and 6 females). Twelve 
(4.1%) participants died after conventional virological failure and so 
were censored in the analysis of pragmatic failure. Participants who 
died were older than those who did not die (P = 0.05), were more 
immunosuppressed (P = 0.01) and more wasted (P = 0.01). 
Participants accrued 1035 person years at risk (pyar) and the 
median follow up time was 2.97 years (IQR), range 0.23 to 7.11 
years. Five years after ART initiation, about 30% of the participants 
had developed conventional failure (Figure 2) and 10% of the 
participants had developed pragmatic virological failure (Figure 3). 
  
Effect of adherence on conventional virological failure: 
Overall, 84 (26.6%) participants developed conventional virological 
failure, a rate of 8.6 per 100 pyar. There were no significant 
differences in failure rates by gender, age and alcohol consumption. 
The median proportion of visits on which good adherence was 
reported was 97.0% (IQR (92-100). Conventional failure rates were 
significantly higher among participants who reported adherence less 
than 90% compared with participants who reported good adherence 
of above 95% of the visits (crude HR 1.38 for linear association with 
10% drop in the proportion of visits with good adherence, 95% CI 
1.23-1.55, P<0.001) (Table 2). 
  
Effect of adherence on pragmatic virological failure: After the 
intensified ART adherence counselling, 28 (33.3%) of the 84 
participants with conventional failure still had persistent VL > 1000 
copies/ml, a pragmatic failure rate of 2.7 per 100 pyar. The 
pragmatic failure rate decreased significantly with increasing age (P 
= 0.04), but increased with decrease in proportion of visits on which 
good adherence was reported (P < 0.001) (Table 3). The 
unadjusted linear hazard ratio indicated that pragmatic failure rate 
increased by 45.0% for every 10% decrease in the proportion of 
visits on which good adherence was reported (HR 1.45, 95%CI 
1.26-1.71; P < 0.001). After adjusting for age, gender, alcohol 
consumption, baseline CD4 counts and baseline VL, the adjusted 
linear hazard ratio for the failure rate per 10% decrease in the 
proportion of visits on which good adherence was reported 
increased to 2.12 (95%CI 1.61-2.79, P < 0.001). 
  
Independent predictors of conventional virological failure: 
After adjusting for age and gender, the only independent predictors 
of conventional virological failure were adherence and alcohol 
consumption. For each drop of 10% in the proportion of visits at 
which a participant achieved good adherence, the rate of failure 
increased by 83% (aHR 1.83, 95%CI 1.50-2.23, P < 0.001). 
Participants who consumed alcohol had 71% higher rate of 
conventional virological failure than those who reported not 
consuming alcohol (aHR 1.71, 95%CI 1.05-2.79, P = 0.03) (Table 
4). 
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Independent predictors of pragmatic failure among 
individuals with conventional failure: We adjusted for apriori 
confounders; age, gender and alcohol consumption to determine 
predictors of pragmatic virological failure among participants with 
conventional virological failure. There was an 88% reduction in the 
odds of pragmatic failure from age group < 30 years to age group 
30-39 years (adjusted odds ratio (aOR) 0.12, 95% CI 0.03-0.57, P = 
0.01) and an 86% reduction in the odds of pragmatic failure from 
age group <30 years to age group 40 years and above (aOR = 
0.14, 95%CI (0.03-0.71) P = 0.02). There was borderline evidence 
of a threefold increase in the odds of pragmatic failure among 
participants who reported consuming alcohol compared to those 
who reported not consuming alcohol (aOR = 3.14, 95% CI 0.95-
10.34), P = 0.06). However, adherence was not significantly 
associated with pragmatic failure among participants with 
conventional failure (P = 0.44) (Table 5). 
  
  
Discussion 
 
In this rural Ugandan cohort, the pragmatic definition of virological 
failure resulted in a 66.7% reduction in the number of patients who 
would have been switched to second line ART based on the 
conventional virological failure definition. The independent 
predictors of conventional virological failure were ART adherence 
and alcohol consumption. Among individuals with conventional 
failure, the independent predictors of pragmatic failure were 
decreasing age and alcohol consumption. Our findings support the 
current ART guidelines recommendation to switch participants only 
after additional intensified ART adherence counselling and thus 
confirmation of true of pragmatic virological failure. This will help 
keep patients longer on first line ART regimen which is cheaper, 
safer and also preserves the more toxic and expensive second line 
ART regimen for as long as possible in a resource limited setting. 
Switching patients basing on conventional virological failure leads to 
higher proportions of patients getting switched unnecessarily. In a 
South African HIV cohort 21.6% of the patients were switched to 
second line due to detection of viraemia following ART initiation 
[28]. In our study, 26.6% of the 316 participants would have been 
switched to second line ART using the conventional failure 
definition, but when we used the pragmatic failure definition, only 
8.9% were switched. The need to keep patients on first line ART 
regimens for as long as possible can be justified by their safety, 
lower cost and lesser pill burden [29]. Patients who fail on the lower 
pill burden and safer first line ART regimen have been shown to 
have a higher likelihood of virological failure after switching to 
second line ART regimen possibly due to poor adherence to a 
regimen with a higher pill burden and greater side effect profile 
[30]. The association between lower adherence and virological 
failure has been reported in other studies where adherence to drug 
refill was an early warning indicator to virological failure [28]. 
  
Decreasing age was the factor most significantly associated with 
pragmatic failure, however the small numbers younger patients 
made it impossible to explore this association in more detail, like 
finding the actual age below which failure is more likely. The higher 
pragmatic failure rates among participants aged below 30 years has 
been found in other studies. In Cameroon, a study on adults taking 
ART demonstrated that age independently predicted virological 
failure and an increase in age had better prediction in terms of 
immune, haematological and virological responses to ART [30]. In 
Nigeria, virological failure among younger participants was 
attributed to poor adherence [31] and poor adherence among 
participants aged 16-29 years was reported in Urban Zambia [32]. 
The social complexity of reasons for ART non-adherence among 
adolescents and young people have also been reported [30]. 
However, the biological reasons for high virological failure rates 
among younger adults need to be understood. In our study, alcohol 
consumption was an independent risk factor for conventional failure 
and was also associated with pragmatic failure, although the 
association was of borderline statistical significance. Previous studies 
have shown that alcohol affects adherence through a complex 
mechanism and a significant association between alcohol use and 
poor ART adherence has been demonstrated before [33-35]. Alcohol 
might also worsen tolerability of ART agents which may lead to 
deliberate skipping of doses to avoid the side effects. Reports from 
a prospective cohort showed that a substantial number of people 
intentionally skip or stop their ART medications when drinking 
alcohol [33]. Most of our study participants were females, other 
studies on ART in SSA have also reported a female dominance 
among participants, in South Africa (67.8%), in Cameroon (77.8%) 
and in Tanzania (64.1%) most of the patients on ART were females 
[27, 36, 37]. Most of our participants were aged below 40 years, 
this is also similar to what has been found in other African settings 
[30]. The low median CD4 count at ART initiation of 156 cells/mm3 
is due to the fact that by the time of universal roll out of ART, many 
PLWHA were already severely immunosuppressed, a finding that is 
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common sub-Saharan Africa where ART is a relatively recent 
intervention [38]. 
  
Strengths: The prospective study design enabled consistent follow 
up of participants for a median period of about 3 to 7 years which 
allowed assessment of the temporal association between virological 
failure and the exposures. This follow up also enhanced strict 
intensive adherence counselling for 6 months among patients with 
conventional virological failure before detecting pragmatic failure. 
Death, migration and missed appointments were well recorded and 
loss to follow up was low at 3.2%, which minimised the likelihood of 
selection bias. The few participants with missing baseline data were 
comparable to those without missing data. Regular viral loads 
measurement reduced the likelihood of misclassification of outcome. 
Participants were recruited from a general population based cohort 
minimising selection bias and enhancing generalizability of findings. 
The study had a robust data collection mechanism, with trained 
staff and laboratory equipment were subjected to regular external 
validity checks and quality assurance to minimise errors in the 
measurement of viral load and CD4 count. 
  
Limitations: Our estimates were subjected to random error by 
having few participants aged below 30 years and above 50 years. 
This undermined exploration of the age effect like to find the actual 
age below or above which failure is more or less likely. Few 
participants had pragmatic virological failure which might have led 
to imprecise estimates and low power to detect associations 
between risk factors and outcome. Participants who died differed 
significantly from those who did not die and were likely to be older, 
have lower BMI and were more immunosuppressed. Treating deaths 
as censored observations might have biased the estimates of 
virological failure especially if those who died were more likely to 
have developed virological failure. The measured self-reported 
alcohol consumption was prone to social desirability bias, and the 
quantity, type and frequency of alcohol consumption was not 
recorded. The likely recall bias arising from self-reported ART 
adherence was minimised by asking participants if they skipped any 
doses in the last 4 days, however, the analysis of adherence as a 
summary variable ignored the temporal variation of adherence. We 
assessed a limited number of potential confounders so virological 
failure estimates might be subjected to residual confounding. We 
did not establish mortality or test ART drug resistance mutations 
within the 6 months participants with virological failure were 
subjected to strict adherence counselling, which would have been 
important in evaluating the safety of the pragmatic failure approach. 
Conclusion 
 
Our findings reinforce the need to sustain viral load testing as a key 
tool in monitoring treatment progress and to use the safe and cheap 
pragmatic approach when switching participants from first to second 
line ART in resource limited settings to preserve second line ART 
regimen. To achieve the 90-90-90 treatment target by 2020 in SSA, 
the strategy of rolling out viral load testing should be supplemented 
with innovative adherence enforcement to achieve sustained viral 
suppression among patients on ART. Maintaining adequate stocks of 
ART and patient tailored counselling especially for the young and 
alcohol users will prevent poor adherence and virological failure. 
National governments should increase funding for recruiting or 
training staff in ART adherence counselling. Qualitative studies are 
however needed to assess the factors responsible for virological 
failure among the alcohol consumers and young people as this will 
help design strategies to address adherence issues and virological 
failure in these groups. 
 
What is known about this topic 
 WHO guidelines currently recommend viral load testing as 
the gold standard for monitoring and confirming 
treatment response; 
 WHO also recommends Intensified adherence counselling 
following an initial high viral load (> 1000 copies/mL) 
before conducting a second viral load test; 
 Adherence is a known independent predictor of virological 
failure. 
What this study adds 
 The study demonstrates the independent predictors for 
both pragmatic and conventional failures including the 
young age and alcohol consumption in African populations 
which will direct policy on the need to design strategies to 
deal with virological failure focusing on these categories; 
 The study also presents a basis for qualitative exploration 
of Virological failure among young people and alcohol 
consumers; 
 The study results show a significant (66.7%) reduction in 
the number of participants unnecessarily switched to 
second line ART if the conventional VF approach was used 
alone which further strengthens the importance of using a 
pragmatic virological failure approach in switching to 
second line ART. 
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Table 1: Participants’ characteristics at ART initiation 
Factor Categories   
Numbers 
N 
[Total=316] 
(%) 
Gender 
Male 115 (36.4) 
Female 201 (63.6) 
Age (Years) 
14 – 29 67 (21.2) 
30 – 39 129 (40.8) 
40 – 49 79 (25.0) 
50+ 41 (13.0) 
Median age (IQR) in years 36.5 (IQR) 
  
Level of education 
None or incomplete primary 213 (67.4) 
Complete primary/some secondary 48 (15.2) 
Complete secondary or higher 55 (17.4) 
Marital status 
Single, separated or widowed 139 (44.0) 
Married or with a steady partner 177 (56.0) 
Number of steady partners at 
enrolment 
None 135 (42.7) 
One 166 (52.5) 
Two or more 15 (4.75) 
Occupation 
Farmer 192 (60.8) 
Trader/seller 42 (13.3) 
Semi-skilled/skilled 18 (5.70) 
Others 64 (20.3) 
Alcohol consumption 
No 223 (70.6) 
Yes 93 (29.4) 
CD4 Counts at ART initiation Median (IQR)           156 ( 73 -200) 
  
CD4 group at ART initiation 
(cells/mm3) 
<50 64 (20.3) 
50 - 199 173 (54.8) 
200+ 79 (25.0) 
1Baseline viral load 
(copies per ml) 
<400 15 (5.5) 
400 – 999 1 (0.4) 
1000-9999 21 (7.8) 
10000-99999 115 (42.3) 
100,000 – 999999 112 (41.2) 
1000000+ 8 (2.9) 
Viral load     1 Median (IQR 3) 81,758 (26,721 - 193,184) 
2Body mass index (BMI)(kg/m2) 
<15 11 (3.5) 
15-18.5 74 (23.8) 
>18.5 226 (72.7) 
Body mass index (2.9) Mean(standard deviation) 20.1 
 
1Baseline viral load has missing data on 44 participants 
2 BMI has missing data for 5 participants ,  IQR - interquartile range 
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Table 2: Factors associated with conventional virological failure; crude failure rates and hazard ratios 
  
Factor 
  
Level 
Number of 
failures N (pyar) 
Failure rate 
Per 100 
pyar 
Crude 
Hazard ratios* 
(95% CI) 
  
P-value1 
Overall   8 (980) 8.6 
  
Gender 
Male 
Female 
28(359) 7.8 1   
0.57 5 (621) 9.0 1.14 (0.72- 1.80) 
Age in years 
14 – 29 23(172) 13.4 1   
  
  
0.28 
30 – 39 34 (436) 7.8 0.65 (0.38–1.10) 
40 – 49 19 (262) 7.3 0.59 (0.32 – 1.10) 
50+ 8 (110) 7.3 0.57 (0.25 -1.27) 
Educational 
Level 
None/incomplete Primary 54(647) 8.3 1   
  
0.34 
incomplete secondary 16 (132) 12.1 1.43  (0 .82 - 2.50) 
Complete secondary 14 (201) 7.0 0.85 (0.47 - 1.53) 
Marital 
Status 
Single separated widowed 34 (452) 7.5 1   
  
0.35 
Married/steady partner 50 (528) 9.5 1.22  (0.37 – 0.78) 
No of partners 
None 34 (460) 7.4 1   
  
0.32 
One 48 (480) 10.0 1.30 (0.25 –0.83) 
Two or more 2 (41) 4.9 0.62 (0.15 -2.60) 
Consumes 
Alcohol 
No 54 (683) 7.9 1   
0.26 Yes 30(298) 10.1 1.29  (0.83 -2.02) 
 Occupation 
Farmer 51 (588) 8.7 1   
  
  
0.99 
Trader/seller 12 (146) 8.2 0.96 (0.51- 1.80) 
Skilled / semi-skilled 4 (44) 9.1 0.95  (0.34- 2.62) 
Other/missing  17 (202) 8.4 0.98 (0.56 – 1.71) 
CD4 at 
ART start 
Cells/ml 
200+ 17 (190) 8.9 1   
  
0.62 
50- <200           46 (590) 7.8 1.02 (0.58-1.78) 
< 50 21 (200) 10.5 1.30 (0.69–2.47) 
2 Baseline viral loads 
(Copies/ml) 
< 1000 2 (56) 3.6 1   
  
0.62 
1000-<10,000 5 (57) 8.8 2.30 (0.45-11.88) 
10000+ 66 (835) 7.9 2.20    (0.56-9.28) 
Proportion of visits on  
which good adherence 
(> 95%) was reported 
95%+ 47 (7) 6.7 1 
  
  
  
<0.001 
90-94% 9 (1.6) 5.7 0.83 (0.41-1.71) 
< 90% 28 (1.2) 23.1 2.99  (1.85-4.82) 
Linear hazard  ratio for 10% drop in the proportion of 
visits good adherence was reported 
1.38 (1.231.55) 
3 Baseline Body mass 
index (BMI) 
Kg/m2 
<18.5 57 (710) 8.0 1   
  
0.68 
15-18.5 23 (233) 9.9 1.22 (0.76-1.99) 
>15 2 (27) 7.4 0.85 (0.21-3.49) 
1P value from the Likelihood Ratio Test                                                                                                              2 Baseline viral load has 
missing data on 11 participants                                                                                                                                      
3BMI has missing data for 2 participants 
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Table 3: Factors associated with pragmatic virological  failure; crude failure rates and hazard ratios 
Factor 
  
Category 
  
No of failures 
N       (pyar) 
Failure 
Rate / 
100pyar 
Hazard ratio 
(95% CI) 
  
P-value1 
Overall   28       (1036) 2.7     
Gender                 
Male 10       (384) 2.6 1   
0.90 Female 18       (652) 2.8 1.03 ( 0.52 –2.23) 
Age (Years) 
14 – 29 12       (184) 6.5 1   
  
  
0.04 
30 – 39 8       (463) 1.7 0.30 ( 0.09-0.71  ) 
40 – 49 5       (272) 1.8 0.31 ( 0.11-0.93  ) 
50+ 3       (117) 2.6 0.43 ( 0.12-1.44  ) 
Level of education 
None or incomplete primary 19       (691) 2.7 1   
  
0.33 
incomplete secondary 6       (138) 4.3 1.52 ( 0.62-3.92  ) 
Complete secondary 3       (207) 1.4 0.61 ( 0.24-1.56  ) 
Marital status 
Single, separated or widowed 11       (471) 2.3 1   
0.33 Married /steady partner 17       (564) 3.0 1.22 ( 0.64-2.67  ) 
2Number of steady partners 
at enrolment 
None 1       (481) 0.2 1 
  
0.23 
One 17       (513) 3.3 1.34 ( 0.56-2.82  ) 
Two or more 0           ---- ---- . 
Alcohol consumption 
No 16       (717) 2.2 1   
0.15 Yes 12       (318) 3.8 1.67 ( 0.81-3.67  ) 
Occupation 
Farmer 17       (654) 2.6 1   
  
  
0.15 
Trader/seller 1       (154) 0.6 0.33 ( 0.03-1.90  ) 
Semi-skilled/skilled 1       (47) 2.1 0.70 ( 0.11-5.30  ) 
Others 9       (211) 4.3 1.60 ( 0.74-3.67  ) 
CD4 count at ART initiation 
(cells/mm3) 
200+ 7       (196) 3.6 1   
  
0.19 
50 – <200 16       (625) 2.6 0.87 (0.36 – 2.12) 
<50 5       (214) 2.3 0.78 (0.25 – 2.45) 
3Baseline viral load 
(copies per ml) 
<1000 1       (58) 1.7 1   
  
0.32 
1000- <10,000 2       (57) 3.5 1.91 ( 0.20-20.8  ) 
10000+ 23       (886) 2.6 1.60 ( 0.20-11.7  ) 
Proportion of visits on which 
good adherence (> 95%) 
was reported 
95%+ 12       (731) 1.6 1 
  
  
  
<0.001 
90-94% 2       (162) 2.2 0.74 (0.16 – 3.29) 
<90% 14       (139) 10.1 5.05 (2.3 –11.05 ) 
Linear hazard ratio for 10% drop in the proportion of 
visits good adherence was reported 
1.45 (1.26 -1.71 ) 
4Body mass 
index  (BMI)(kg/m2) 
>18.5 16       (743) 2.2 1   
  
0.33 
15-18.5 10       (255) 3.9 1.93 ( 0.87-4.25 ) 
>18.5 1       (28) 3.6 1.47 ( 0.20-11.11) 
 1P value from the Likelihood Ratio Test 
 2Data was missing on the number of steady partners at enrolment for 10 participants with      virological failure 
3 Baseline viral load has missing data on 2 participants 
4BMI has missing data4 for 1 participant 
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Table 4: Independent predictors of conventional virological failure-results from fitting 
cox’s models 
 Factor Level aHR (95% CI) P-value1 
Age in years 
  
14 – 29 1 
  
0.13 
30 – 39 0.70 (0.39 - 1.25) 
40 – 49 0.62 (0.31 - 1.21) 
50+ 0.55(0.22 - 1.33) 
Proportion of 
adherent visits 
Per 10% drop in 
proportion of visits 
on which 
adherence of 95% 
was reported 
1.83 (1.50 - 2.23) <0.001 
Gender 
Male 1 
0.67 
Female 1.12  (0.67 - 1.87) 
Consumes alcohol 
No 1 
0.03 
Yes 1.71(1.05 - 2.79) 
aHR (95%CI) - adjusted Hazard ratio (95% confidence interval) 
1P-value from the likelihood ratio test 
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Table 5: Factors associated with pragmatic failure among individuals with conventional failure - results from logistic regression models 
Factor Level 
Convention 
Failures 
NC=84 
Pragmatic 
Failures 
NP=28 
Proportion of 
conventional  failures 
who failed 
pragmatically (NP/NC) 
x 100 
Adjusted odds 
ratios 
(95% CI) 
P-value1 
Age in years 
14 – 29 23 12 (52.2%) 1 
0.02 
30 – 39 34 8 (23.5%) 
0.12 
(0.03 – 0.57) 
40 + 27 8 (29.6%) 
0.14 
(0.03 – 0.71) 
Proportion of visits 
adherence of > 95 
was reported 
95%+ 47 12 (25.5%) 1 
0.44 
<95% 37 16 (43.2%) 
1.12 
(0.84-1.50)2 
Consumes alcohol 
No 54 16 (29.6%) 1 
0.06 
Yes 30 12 (40.0%) 
3.14 
(0.95-10.34) 
1P-value from the likelihood ratio test       
2Linear aOR showing the increase in failure rates for each 10% decrease in proportion of visits with good adherence          NC- number 
with conventional virological failure                                                                                                     NP – number with pragmatic 
virological failure 
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Figure 1: Conceptual framework for factors affecting virological failure and a pragmatic 
approach to diagnosis of virological failure 
 
 
 
Figure 2: Conventional failure survival experience of HIV infected participants 
since ART initiation–Kaplan Meir estimate 
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Figure 3: Pragmatic failure survival experience of HIV infected participants since ART initiation–Kaplan Meir 
estimate 
 
